![Taltz 80 mg solution for injection in pre-filled syringe - Summary of Product Characteristics (SmPC) - (emc) Taltz 80 mg solution for injection in pre-filled syringe - Summary of Product Characteristics (SmPC) - (emc)](https://www.medicines.org.uk/emc/images/spc/spc~32054~14~image24.png)
Taltz 80 mg solution for injection in pre-filled syringe - Summary of Product Characteristics (SmPC) - (emc)
![LB0005 MULTICENTRE, RANDOMISED, OPEN-LABEL, ASSESSOR-BLINDED, PARALLEL-GROUP HEAD-TO-HEAD COMPARISON OF THE EFFICACY AND SAFETY OF IXEKIZUMAB VERSUS ADALIMUMAB IN PATIENTS WITH PSORIATIC ARTHRITIS NAIVE TO BIOLOGIC DISEASE-MODIFYING ANTI-RHEUMATIC ... LB0005 MULTICENTRE, RANDOMISED, OPEN-LABEL, ASSESSOR-BLINDED, PARALLEL-GROUP HEAD-TO-HEAD COMPARISON OF THE EFFICACY AND SAFETY OF IXEKIZUMAB VERSUS ADALIMUMAB IN PATIENTS WITH PSORIATIC ARTHRITIS NAIVE TO BIOLOGIC DISEASE-MODIFYING ANTI-RHEUMATIC ...](https://ard.bmj.com/content/annrheumdis/78/Suppl_2/261/F2.large.jpg)
LB0005 MULTICENTRE, RANDOMISED, OPEN-LABEL, ASSESSOR-BLINDED, PARALLEL-GROUP HEAD-TO-HEAD COMPARISON OF THE EFFICACY AND SAFETY OF IXEKIZUMAB VERSUS ADALIMUMAB IN PATIENTS WITH PSORIATIC ARTHRITIS NAIVE TO BIOLOGIC DISEASE-MODIFYING ANTI-RHEUMATIC ...
![A 52-week, open-label study of the efficacy and safety of ixekizumab, an anti-interleukin-17A monoclonal antibody, in patients with chronic plaque psoriasis - ScienceDirect A 52-week, open-label study of the efficacy and safety of ixekizumab, an anti-interleukin-17A monoclonal antibody, in patients with chronic plaque psoriasis - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S0190962214017794-gr1.jpg)
A 52-week, open-label study of the efficacy and safety of ixekizumab, an anti-interleukin-17A monoclonal antibody, in patients with chronic plaque psoriasis - ScienceDirect
![Ixekizumab Demonstrates Improvement Comparable to Adalimumab Across ACR Components in Biologic-Naïve Patients with Psoriatic Arthritis - ACR Meeting Abstracts Ixekizumab Demonstrates Improvement Comparable to Adalimumab Across ACR Components in Biologic-Naïve Patients with Psoriatic Arthritis - ACR Meeting Abstracts](https://acrabstracts.org/wp-content/uploads/2019/08/GTUOHVCE-683328-1-ANY-1-.jpg)
Ixekizumab Demonstrates Improvement Comparable to Adalimumab Across ACR Components in Biologic-Naïve Patients with Psoriatic Arthritis - ACR Meeting Abstracts
![Ixekizumab for patients with non-radiographic axial spondyloarthritis (COAST-X): a randomised, placebo-controlled trial - The Lancet Ixekizumab for patients with non-radiographic axial spondyloarthritis (COAST-X): a randomised, placebo-controlled trial - The Lancet](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/9b996016-dd72-4ddd-a43d-473a0a0c00d4/gr2_lrg.jpg)
Ixekizumab for patients with non-radiographic axial spondyloarthritis (COAST-X): a randomised, placebo-controlled trial - The Lancet
![Fillable Online accessdata fda LABEL. TALTZ (ixekizumab) injection, Eli Lilly and Company - accessdata fda Fax Email Print - pdfFiller Fillable Online accessdata fda LABEL. TALTZ (ixekizumab) injection, Eli Lilly and Company - accessdata fda Fax Email Print - pdfFiller](https://www.pdffiller.com/preview/101/261/101261840.png)
Fillable Online accessdata fda LABEL. TALTZ (ixekizumab) injection, Eli Lilly and Company - accessdata fda Fax Email Print - pdfFiller
![Long‐term efficacy and safety results from an open‐label phase III study (UNCOVER‐J) in Japanese plaque psoriasis patients: impact of treatment withdrawal and retreatment of ixekizumab - Umezawa - 2019 - Journal of Long‐term efficacy and safety results from an open‐label phase III study (UNCOVER‐J) in Japanese plaque psoriasis patients: impact of treatment withdrawal and retreatment of ixekizumab - Umezawa - 2019 - Journal of](https://onlinelibrary.wiley.com/cms/asset/4d29e6d9-c55c-4c6c-bd56-be17ee5dd35b/jdv15292-fig-0001-m.jpg)
Long‐term efficacy and safety results from an open‐label phase III study (UNCOVER‐J) in Japanese plaque psoriasis patients: impact of treatment withdrawal and retreatment of ixekizumab - Umezawa - 2019 - Journal of
![Long‐term efficacy and safety of ixekizumab in Japanese patients with erythrodermic or generalized pustular psoriasis: subgroup analyses of an open‐label, phase 3 study (UNCOVER‐J) - Okubo - 2019 - Journal of the Long‐term efficacy and safety of ixekizumab in Japanese patients with erythrodermic or generalized pustular psoriasis: subgroup analyses of an open‐label, phase 3 study (UNCOVER‐J) - Okubo - 2019 - Journal of the](https://onlinelibrary.wiley.com/cms/asset/219c7238-d4c7-4611-b5d3-8311d6411004/jdv15287-fig-0001-m.jpg)
Long‐term efficacy and safety of ixekizumab in Japanese patients with erythrodermic or generalized pustular psoriasis: subgroup analyses of an open‐label, phase 3 study (UNCOVER‐J) - Okubo - 2019 - Journal of the
![Figure 3. | Safety and Efficacy of Open-label Subcutaneous Ixekizumab Treatment for 48 Weeks in a Phase II Study in Biologic-naive and TNF-IR Patients with Rheumatoid Arthritis | The Journal of Rheumatology Figure 3. | Safety and Efficacy of Open-label Subcutaneous Ixekizumab Treatment for 48 Weeks in a Phase II Study in Biologic-naive and TNF-IR Patients with Rheumatoid Arthritis | The Journal of Rheumatology](https://www.jrheum.org/content/43/2/289/F4.large.jpg)
Figure 3. | Safety and Efficacy of Open-label Subcutaneous Ixekizumab Treatment for 48 Weeks in a Phase II Study in Biologic-naive and TNF-IR Patients with Rheumatoid Arthritis | The Journal of Rheumatology
![Efficacy and Safety of Ixekizumab Through 5 Years in Moderate-to-Severe Psoriasis: Long-Term Results from the UNCOVER-1 and UNCOVER-2 Phase-3 Randomized Controlled Trials | SpringerLink Efficacy and Safety of Ixekizumab Through 5 Years in Moderate-to-Severe Psoriasis: Long-Term Results from the UNCOVER-1 and UNCOVER-2 Phase-3 Randomized Controlled Trials | SpringerLink](https://media.springernature.com/lw685/springer-static/image/art%3A10.1007%2Fs13555-020-00367-x/MediaObjects/13555_2020_367_Fig1_HTML.png)
Efficacy and Safety of Ixekizumab Through 5 Years in Moderate-to-Severe Psoriasis: Long-Term Results from the UNCOVER-1 and UNCOVER-2 Phase-3 Randomized Controlled Trials | SpringerLink
![Multicentre, randomised, open-label, parallel-group study evaluating the efficacy and safety of ixekizumab versus adalimumab in patients with psoriatic arthritis naïve to biological disease-modifying antirheumatic drug: final results by week 52 | Annals Multicentre, randomised, open-label, parallel-group study evaluating the efficacy and safety of ixekizumab versus adalimumab in patients with psoriatic arthritis naïve to biological disease-modifying antirheumatic drug: final results by week 52 | Annals](https://ard.bmj.com/content/annrheumdis/79/10/1310/F3.large.jpg)
Multicentre, randomised, open-label, parallel-group study evaluating the efficacy and safety of ixekizumab versus adalimumab in patients with psoriatic arthritis naïve to biological disease-modifying antirheumatic drug: final results by week 52 | Annals
![Efficacy and safety of ixekizumab over 4 years of open-label treatment in a phase 2 study in chronic plaque psoriasis - ScienceDirect Efficacy and safety of ixekizumab over 4 years of open-label treatment in a phase 2 study in chronic plaque psoriasis - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S019096221830505X-gr3.jpg)
Efficacy and safety of ixekizumab over 4 years of open-label treatment in a phase 2 study in chronic plaque psoriasis - ScienceDirect
![Early Onset of Clinical Improvement with Ixekizumab in a Randomized, Open- label Study of Patients with Moderate-to-severe Plaque Psoriasis – JCAD | The Journal of Clinical and Aesthetic Dermatology Early Onset of Clinical Improvement with Ixekizumab in a Randomized, Open- label Study of Patients with Moderate-to-severe Plaque Psoriasis – JCAD | The Journal of Clinical and Aesthetic Dermatology](https://jcadonline.com/wp-content/uploads/JCADMAY2018GoldblumFigure1.jpg)
Early Onset of Clinical Improvement with Ixekizumab in a Randomized, Open- label Study of Patients with Moderate-to-severe Plaque Psoriasis – JCAD | The Journal of Clinical and Aesthetic Dermatology
![Taltz 80 mg solution for injection in pre-filled syringe - Summary of Product Characteristics (SmPC) - (emc) Taltz 80 mg solution for injection in pre-filled syringe - Summary of Product Characteristics (SmPC) - (emc)](https://www.medicines.org.uk/emc/images/spc/spc~32054~14~image4.png)
Taltz 80 mg solution for injection in pre-filled syringe - Summary of Product Characteristics (SmPC) - (emc)
![Efficacy and safety of ixekizumab over 4 years of open-label treatment in a phase 2 study in chronic plaque psoriasis - ScienceDirect Efficacy and safety of ixekizumab over 4 years of open-label treatment in a phase 2 study in chronic plaque psoriasis - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S019096221830505X-gr2.jpg)